Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06664814 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorStart date: Sep 20, 2026 to Oct 4, 2026Eligibility criteria expanded, about 34 words · Study description expanded, about 8 wordsShow 2 more changesShow less
Eligibility criteria expanded, about 34 words
Study description expanded, about 8 words
MinorStart date: Sep 17, 2026 to Sep 20, 2026v432
NotablePrimary completion pushed from Nov 30, 2027 to Nov 11, 2030Completion pushed from Dec 1, 2027 to Dec 1, 2030 · Start date: Sep 16, 2026 to Sep 17, 2026v431Show 2 more changesShow less
Completion pushed from Dec 1, 2027 to Dec 1, 2030
Start date: Sep 16, 2026 to Sep 17, 2026
MinorStart date: Sep 15, 2026 to Sep 16, 2026v430
NotablePrimary completion date: Nov 30, 2027 to Nov 11, 2030Completion date: Dec 1, 2027 to Dec 1, 2030 · Start date: Sep 14, 2026 to Sep 15, 2026v429Show 2 more changesShow less
Completion date: Dec 1, 2027 to Dec 1, 2030
Start date: Sep 14, 2026 to Sep 15, 2026
MinorStart date: Sep 10, 2026 to Sep 14, 2026v428
MinorStart date: Sep 9, 2026 to Sep 10, 2026v427
MinorStart date: Sep 8, 2026 to Sep 9, 2026v426
MinorStart date: Sep 7, 2026 to Sep 8, 2026v425
MinorStart date: Sep 6, 2026 to Sep 7, 2026v424
MinorStart date: Sep 3, 2026 to Sep 6, 2026v423
MinorStart date: Sep 2, 2026 to Sep 3, 2026v422
MinorStart date: Sep 1, 2026 to Sep 2, 2026v421
NotablePrimary endpoint(s) modifiedStart date: Aug 31, 2026 to Sep 1, 2026v420Show 1 more changeShow less
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background:
Podocyte diseases are a group of kidney conditions that include focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and membranous nephropathy (MN). In these conditions, specialized kidney cells called podocytes, which help prevent protein from leaking into the urine, are damaged. This can result in high levels of protein in the urine and, over time, worsening kidney function. In some people, the disease may progress to kidney failure requiring dialysis or a kidney transplant. Several treatments are currently available and can be beneficial, but they may cause significant side effects and may not work well for everyone. Therefore, there is a need for safer and more effective treatments for people with these types of kidney conditions.
Objective:
To test a study drug (ManNAc) in people with a podocyte disease, that includes Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), or Membranous Nephropathy (MN).
Eligibility:
People aged 18 years and older with a podocyte disease, that includes Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), or Membranous Nephropathy (MN).
Design:
Participants will have 5 to 6 clinic visits over 14 weeks. Two of the visits will require overnight stays for 2 or 3 nights.
ManNAc is a white powder that comes in a sachet. It is dissolved in water and taken twice a day by mouth. Participants will take their first dose at the clinic. They will learn how to store ManNAc and prepare each dose. They will record their doses in a diary. They will also write down any adverse effects or troubles they have using the drug at home.
During clinic visits, participants will have physical exams with blood and urine tests. They will complete questionnaires about their health, sleep habits, and fatigue symptoms.
During overnight visits, participants will also have 24-hour urine collection.
A study team member will call participants 1 week after the first dose to check on their health. Follow-up phone calls will then be every 2 weeks after each clinic visit.
Participants may meet with a dietitian to discuss nutrition while taking the ManNAc.
Participants may choose to have genetic tests.